Blogs
Oligonucleotide therapeutics continue to reshape drug development by targeting disease pathways at the genetic level. Antisense oligonucleotides (ASOs), small interfering RNAs (siRNAs), and antibody-RNA conjugates (ARCs) are expanding the range of treatable diseases, particularly for targets that were previously considered inaccessible to conventional therapeutics. As these modalities evolve,…
Blogs
In today’s fast-moving drug development landscape, bioanalytical continuity and end-to-end support aren’t just conveniences, they’re competitive advantages. Sponsors navigating complex modalities like gene therapies, ADCs, oligonucleotides, and biologics need a partner who can keep pace with aggressive timelines, shifting priorities, and evolving regulatory expectations. Why Continuity Matters in…
Posters & Papers
Discover in this poster presented by Taylor Dufield at WRIB 2026 about a fit-for-purpose multiplex LC–MS/MS workflow combining online and offline anti-peptide immunoprecipitation that enables sensitive, selective quantitation of protein biomarkers and binding partners from a single digested tissue sample across multiple species using a validated ICH M10-aligned approach.
Posters & Papers
Discover in this poster presented by Ryan Darling at WRIB 2026 on how a validated hybrid immunoaffinity LC–MS/MS method using a surrogate peptide and 2D chromatography enables selective, sub-ng/mL quantitation of a KLK1 analog in human plasma, overcoming LBA limitations caused by near-identical endogenous KLK1. If you have…
Blogs
Developing a robust Pharmacokinetic (PK) assay for biotherapeutics often presents unforeseen biological hurdles. Occasionally, a traditional Ligand Binding Assay (LBA) may yield inconsistent data. In this particular case, the LBA assay was not reliably detecting drug in the matrix, potentially indicating some matrix stability issue during method development. In…
Posters & Papers
This presentation, given at the 2025 AAPS PharmSci Conference by Dawn Dufield, PhD, Scientific Officer of Mass Spectrometry at KCAS Bio, reviews Bioanalytical Strategies for Therapeutic Drugs and Their Conjugates (ADCs, Oligos, siRNA, ASOs and AOCs/ARCs) by QqQ/HRMS. If you have any questions about these services or any…
Blogs
Drug discovery is an essential part of the drug development process. Researchers test candidates to identify those suitable for regulated animal studies and, ultimately, clinical trials. Bioanalytical discovery involves assessing a compound’s physiochemical properties,…
Posters & Papers
Discover in this poster presented by Ryan Darling at the AAPS National Biotechnology Conference 2025 on the use of a hybrid LC-MS/MS approach for the quantitation of total antibody TAb and intact Antibody Drug Conjugate (ADC). If you have any questions about these services or any…
Posters & Papers
Discover in this poster presented by Bryan Parmentier at WRIB 2025, our work for the sponsor Lilly on the “Determination of Cisplatin in Human Plasma by LC-MS/MS using Hemoglobin to Overcome Matrix Effects“. If you have any questions about these services or any others offered by KCAS Bio,…
Blogs
ADCs represent a promising class of targeted therapies, and understanding the intricacies of their analysis is crucial for their successful development. In this blog, we address common questions to guide you through the various considerations involved in ADC research and testing. We will cover key topics related to…
Blogs
Antibody-drug conjugates (ADCs) have been conventionally developed for a wide range of oncological applications since the first ADC approval in 2000 by the FDA. Typically, an ADC consists of three main components: antibody, linker conjugate, and therapeutic drug (payload). The mechanism of an ADC involves the antibody binding to a…
Podcasts
In episode 84 of “The Weekly Bioanalysis”, our special guest, Bryan Parmentier, joins Dom and John to discuss his background and current role at KCAS Bio, offering insights into the field of small molecule method development. He delves into the typical challenges encountered when working with LC-MS analytes, and…